65,437 trials
Asthma
Primary: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) — 0.09; 0.17; 0.01 Liter — p=0.022
Diphtheria · Acellular Pertussis · Tetanus
Primary: Number of Subjects Reporting Serious Adverse Events — 3 Subjects
Depressive Disorder, Major
Primary: Percentage of Participants With Depressive Recurrence After Time (t) in Days — 0.68; 2.11; 1.37; 2.11 percentage of participants — p=<0.001
Chronic Insomnia
Primary: Percentage of Participants Who Discontinued Zolpidem Therapy — 28.8; 32.7 Percentage of participants — p=0.484
Attention Deficit Hyperactivity Disorder · Attention Deficit Disorders With Hyperactivity · Attention Deficit Hyperactivity Disorders
Primary: Change in ADHD-RS-IV Total Score From Baseline at Up to One Year — -24.8 Units on a scale — p=< 0.0001
Rhinitis · Urticaria
Primary: Adverse Events — 41; 15; 1 adverse events reported
Hepatitis C, Chronic · Hepacivirus
Primary: Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use. — 104; 102; 102; 102 Satisfied Participants
Depressive Disorder
Primary: Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score — 19.8; 19.4; 14.7; 14.6 Score in scale — p=0.805
Breast Cancer
Primary: Best Tumor Response — 0; 0; 8; 20 participants
Glaucoma,Open-Angle · Ocular Hypertension
Primary: Change in Intraocular Pressure (IOP): Baseline to Month 3 — -5.3; -6.8; -4.1 mmHg
Gout
Primary: Average Percent Difference in Area Between Visits — 29 mm²
Gout
Primary: Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). — 48; 65; 69; 22 Percentage of subjects — p=<0.001
Ovarian Neoplasms
Primary: Number of Participants With Complete Response — 0 participants
Hyperuricemia · Gout
Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785
Gout
Primary: Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit. — 45.2; 67.1; 42.1 percentage of subjects — p=0.233